The trial was a double-blind, randomized, active comparator study of LT-NS001 (formerly MX-1094) vs. naproxen in patients aged 45 to 70 years.
In the trial, the patients underwent upper endoscopies at baseline and on day seven. The data shows patients receiving LT-NS001 experienced statistically fewer endoscopically confirmed gastric ulcers compared to subjects receiving naproxen.
There were no serious adverse events and LT-NS001 was well tolerated, said the company.